Format

Send to

Choose Destination
Expert Opin Emerg Drugs. 2018 Mar;23(1):17-23. doi: 10.1080/14728214.2018.1446943. Epub 2018 Mar 12.

Emerging treatment options for uterine fibroids.

Author information

1
a Catholic University of Louvain, Société de Recherche pour l'Infertilité (SRI) , Brussels , Belgium.
2
b Gedeon Richter/Preglem S.A ., Geneva , Switzerland.
3
c Institut du Sein et de Chirurgie Gynécologique d'Avignon, Polyclinique Urbain V (ELSAN Group) , Avignon , France.
4
d Gynecology Department , Cliniques Universitaires St-Luc , Brussels , Belgium.
5
e Pôle de Gynécologie , Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain , Brussels , Belgium.

Abstract

Uterine fibroids (also known as leiomyomas or myomas) are the most common form of benign uterine tumors. Current management strategies involve mainly surgical interventions, but the choice of treatment is guided by patient age and desire to preserve fertility or avoid 'radical' surgery such as hysterectomy. Areas covered: There is growing evidence of the crucial role of progesterone pathways in the pathophysiology of uterine fibroids, leading to increasing use of selective progesterone receptor modulators (SPRMs) such as ulipristal acetate. We searched all published studies on medical management of fibroids with SPRMs. Expert opinion: The need for alternatives to surgical intervention is very real, especially for women seeking to preserve their fertility. These options now exist, with SPRMs proven to treat fibroid symptoms effectively. Gynecologists now have new tools in their armamentarium, opening up novel strategies for the management of uterine fibroids.

KEYWORDS:

Uterine fibroids; infertility; leiomyomas; medical therapy; myomectomy; selective progesterone receptor modulators; surgery; ulipristal acetate

PMID:
29486606
DOI:
10.1080/14728214.2018.1446943
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center